Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, By Treatment (Medication, Supplements, Blood Transfusion and Bone Marrow Transplant), Drugs (Eculizumab, Ravulizumab and Others), Route of Administration (Oral and Parenteral), Distribution Channel (Direct, Online Pharmacy, Retailers and Others), End-Users (Hospitals, Homecare, Specialty Clinics and Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2029